Background. Left ventricular hypertrophy (LVH) is an independent risk factor for cardiovascular morbidity and mortality in essential hypertension (EH). Several hemodynamic and nonhemodynamic factors have been involved in the development of LVH in hypertension, including abnormalities in cellular ion mobilization.
L eft ventricular hypertrophy (LVH) measured by echocardiography is exhibited by about one half of essential hypertensive (EH) patients1 and is thought to represent an index of the severity of hypertension. Previous studies have shown that echocardiographically detected LVH predicts cardiovascular complications during 5-year follow-up periods in hypertensive men. 2 The severity of high blood pressure and the duration of the hypertensive disease are the major determinants of LVH. Nevertheless, the fact that not all EH patients exhibit LVH and that cardiac enlargement is detected in some normotensive subjects with a family history of hypertension suggests that nonhemodynamic factors must also be involved in the pathogenesis of LVH in hypertension.
In recent years, convincing evidence has been presented that alterations in the intracellular pool of ions, especially Na' and Ca2 , may play a role in the pathogenesis of EH. Abnormalities of Na' and Ca 2 transport pathways have been reported in red blood cells from EH patients and rats with primary hypertension.3-7 Several attempts have been aspects of hypertension, and some authors have reported that patients with an increased maximal rate of Na+-Li+ countertransport exhibit some differences in severity of high blood pressure,5 lipid profile,8 and plasma renin activity. 5, 6 With respect to LVH, Yap et a19 reported that patients with elevated Na+-LiW countertransport showed a higher incidence of LVH (71%) measured by ECG (Sokolow-Lyon index) than hypertensive persons without this transport abnormality (19%). Likewise, Nosadini et al,10 using M-mode echocardiography, observed a significantly higher left ventricular mass index (LVMI) in patients with elevated erythrocyte Na+-Li+ countertransport.
On the basis of these previous considerations, we have were performed using the following equation for Na+ efflux via Na+-K+ pump and via Na+-K+-Clcotransport:
where Vma, is the maximal rate of ouabain-sensitive or bumetanide-sensitive Na+ efflux and KNa represents the apparent dissociation constant for internal Na+ (Nai+).
For Na+-Li+ countertransport (Li+-stimulated Na+ efflux), the same equation was used without the exponent 3.
Na+ leak was expressed as the constant of permeability, calculated by dividing the ouabain bumetanideresistant Na+ efflux in fresh cells by the internal Na+ content.
Measurement of the Na+-H+ exchange. Na+ influx via Na+-H+ exchange was determined in acid-loaded cells by use of a modified protocol described by Canessa et al. 7 Briefly, erythrocytes were depleted of internal Na+ by the above-described loading procedure with nystatin. Two aliquots of cells were prepared and incubated for 60 minutes at 37°C in a medium containing (mmol/L) KCl 140, MgCl2 1, glucose 5, and MOPS-Tris 10 buffered at pH 7.4 (first aliquot) or pH 6 (second aliquot). The (Fig 2, top and bottom) . Discussion Our results show that among the parameters evaluated, the increased rate of the erythrocyte Na+-H+ exchange and the decreased maximal rate of the Na+-K+-Clcotransport system are significantly and independently correlated with the LVMI in patients with EH.
Cardiac hypertrophy is an independent risk factor for cardiovascular morbidity and mortality in EH patients. The hyperactivity of the Na+-HW exchanger is known to produce a simultaneous net Na' influx and H' efflux from the cell. In different cell types, this transport system exhibits distinct characteristics that affect its sensitivity to amiloride and its analogues, the activation kinetics by Na' and HW, and a variety of responses to intracellular messengers. It seems that at least two different subtypes of this transport system exist, the first involving nonepithelial cells and the basolateral domain of epithelial cells and the second involving the apical domain of polarized epithelial cells. 27 In nonepithelial cells, such as circulating cells (platelets and probably erythrocytes) and myocardiocytes, Na+-HW exchange activity is enhanced by increases in cytosolic Ca21 concentration and by the activation of the phospholipase C and protein kinase C pathway by vasoactive substances (angiotensin II) and growth factors (plateletderived growth factor, epidermal growth factor).28 Furthermore, in myocardial and vascular smooth muscle cells, the increased Na' entry via Na+-HW exchange could lead to a rise in intracellular Ca21 content through an inhibition of sarcolemmal Na+-Ca2+ exchange, thereby promoting increased contractility.29 Whether this abnormality is primary and genetically determined or secondary to the prior activation of intracellular messengers remains to be established.
In conclusion, our results suggest that the increased intraerythrocyte Na+ content observed in hypertensive patients exhibiting LVH could be related basically to both the hyperactivity of the Na+-H+ exchanger and the hypoactivity of the Na+-K+-Cl-cotransport system. The lack of relation between blood pressure values and left ventricular mass in hypertensive patients strengthens the hypothesis that other factors than blood pressure are also involved in the development of LVH in EH. The enhancement of the Na+-H+ exchanger in erythrocytes of EH patients seems to be a good biological marker of myocardial hypertrophy.
